- Home
- NGNE vs CYRX Comparison
NGNE vs CYRX Comparison
Compare NGNE & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- CYRX
- Stock Information
- Founded
- NGNE 2003
- CYRX 1999
- Country
- NGNE United States
- CYRX United States
- Employees
- NGNE N/A
- CYRX N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- CYRX Biotechnology: Pharmaceutical Preparations
- Sector
- NGNE Health Care
- CYRX Health Care
- Exchange
- NGNE Nasdaq
- CYRX Nasdaq
- Market Cap
- NGNE 352.4M
- CYRX 422.6M
- IPO Year
- NGNE N/A
- CYRX N/A
- Fundamental
- Price
- NGNE $16.62
- CYRX $8.16
- Analyst Decision
- NGNE Strong Buy
- CYRX Buy
- Analyst Count
- NGNE 6
- CYRX 7
- Target Price
- NGNE $60.80
- CYRX $13.14
- AVG Volume (30 Days)
- NGNE 223.3K
- CYRX 261.6K
- Earning Date
- NGNE 11-18-2024
- CYRX 03-11-2025
- Dividend Yield
- NGNE N/A
- CYRX N/A
- EPS Growth
- NGNE N/A
- CYRX N/A
- EPS
- NGNE N/A
- CYRX N/A
- Revenue
- NGNE $925,000.00
- CYRX $226,113,000.00
- Revenue This Year
- NGNE N/A
- CYRX N/A
- Revenue Next Year
- NGNE N/A
- CYRX $7.70
- P/E Ratio
- NGNE N/A
- CYRX N/A
- Revenue Growth
- NGNE N/A
- CYRX N/A
- 52 Week Low
- NGNE $14.44
- CYRX $5.32
- 52 Week High
- NGNE $74.49
- CYRX $20.11
- Technical
- Relative Strength Index (RSI)
- NGNE 29.82
- CYRX 53.74
- Support Level
- NGNE $17.63
- CYRX $6.97
- Resistance Level
- NGNE $20.29
- CYRX $8.97
- Average True Range (ATR)
- NGNE 1.49
- CYRX 0.55
- MACD
- NGNE -0.17
- CYRX -0.08
- Stochastic Oscillator
- NGNE 7.29
- CYRX 59.50
About NGNE Neurogene Inc.
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.